0					(A	Amount Rs. in Lac
Sr. No.	Particulars	~ 31-12-2006	For the Quarter ended 31-12-2005	For the period ended 31-12-2006	For the period ended 31-12-2005	For the year ended 31-03-2006
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	INCOME					
1	Sales/ Income from Operations	3,575.97	2,522.63	9,809.90	7,041.04	11,086.2
	Less : Excise Duty	58.17	53.43	166.55	176.08	202.6
	Net Sales	3,517.79	2,469.20	9,643.35	6,864.96	10,883.6
2	Other Income	271.03	222.24	583.23	386.15	608.9
	Total Income	3,788.83	2,691.44	10,226.58	7,251.11	11,492.5
	EXPENDITURE					
3	a. (Increase)/Decrease in Stocks of					
5	WIP & Finished/Traded Goods	(76.34)	(56.70)	(112.93)	(406.15)	(564.5
	b. Cost of Materials/Purchase of Traded Goods	1,960.23	1,309.92	4,966.66	3,642.01	6,185.8
	c. Staff Cost	407.57	298.18	1,100.07	893.73	1,301.9
	d. Other Expenditure	957.37	649.95	2,695.84	1,713.29	2,673.0
	Total Expenditure	3,248.83	2,201.35	8,649.65	5,842.88	9,596.3
4	Profit before Interest, Depreciation & Tax	540.00	490.09	1,576.93	1,408.23	1,896.2
5	Interest	98.23	60.80	292.15	188.42	244.8
6	Depreciation/Amortisation	70.98	49.07	209.40	146.03	208.2
7	Profit Before Tax (4-5-6)	370.79	380.22	1,075.38	1,073.78	1,442.6
8	Provision for Tax					
	- Current Tax	47.00	36.00	120.00	91.00	131.
	- MAT Credit Entitlement	(47.00)	-	(120.00)	-	(120.0
	- Deferred Tax	-	90.00	-	113.00	334.5
	- Fringe Benefit Tax	12.24	3.04	24.70	11.52	23.6
	- Tax of Earlier Years	-	-	-	-	0.2
9	Profit After Tax (7-8)	358.54	251.18	1,050.67	858.26	1,073.0
	Paid up Equity Capital	1,274.74	1,274.74	1,274.74	1,274.74	1,274.7
						5,826.8
	EPS - Fully Diluted (Rs.) - Not annualised * Aggregate of Non Promoters shareholding : -	2.81*	1.97*	8.24*	6.73*	9.6
15	- Number of shares (Face value Rs.10 each)	7,055,135	6,894,600	7,055,135	6,894,600	6,898,23
	- Percentage of shareholding	55.35	54.09	55.35	54.09	54.1
	- i creentage of shareholding	00100				
		00100				
	25 :-					
1)	es :- The Company has only one segment of activity namely	'Pharmaceuticals'.		the meeting of th	Preside of Directo	and the Commo
1)	es :- The Company has only one segment of activity namely The above financial results reviewed by the Audit Com	'Pharmaceuticals'.		the meeting of the	e Board of Directo	ors of the Compa
1)	25 :- The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor held on 31st January, 2007.	'Pharmaceuticals'. nmittee, have been	taken on record at	0		ors of the Compa
1) 2)	es :- The Company has only one segment of activity namely The above financial results reviewed by the Audit Com	'Pharmaceuticals'. 1mittee, have been d Review of the res	taken on record at sults for the quarter	ended 31st Decer	nber, 2006.	ors of the Compa
2) 3)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out	taken on record at sults for the quarter of the GDR issue of	ended 31st Decer f Rs. 4,402.35 Lacs	nber, 2006.	
1) 2) 3) 4) 5)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year.	'Pharmaceuticals'. ımittee, have been d Review of the res December, 2006 out d basis. The actual	taken on record at sults for the quarter of the GDR issue of provision for inco	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre	nber, 2006. ed tax will be mad	de at the end of t
1) 2) 3) 4) 5)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee	'Pharmaceuticals'. amittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits'' for the cu	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has	r ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir	nber, 2006. ed tax will be mad	de at the end of t
1) 2) 3) 4) 5) 6)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Corr held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the	'Pharmaceuticals'. mittee, have been d Review of the res December, 2006 out d basis. The actual Benefits'' for the cr Reserves and Surpl	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir financial year.	nber, 2006. ed tax will be mad 1 the above and ac	de at the end of t
1) 2) 3) 4) 5) 6)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee	'Pharmaceuticals'. nmittee, have been d Review of the res December, 2006 out d basis. The actual Benefits'' for the cr Reserves and Surpl Drganic Chemicals	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phan	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir financial year. maceutical Produ	nber, 2006. ed tax will be mad the above and ac cts of India Ltd.,	de at the end of Iditional liability which are,pendi
1) 2) 3) 4) 5) 6)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Com- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O	'Pharmaceuticals'. nmittee, have been d Review of the res December, 2006 out d basis. The actual Benefits'' for the cr Reserves and Surpl Drganic Chemicals	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phan	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir financial year. maceutical Produ	nber, 2006. ed tax will be mad the above and ac cts of India Ltd.,	de at the end of Iditional liability which are,pendi
1) 2) 3) 4) 5) 6) 7)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors C approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o	'Pharmaceuticals'. mittee, have been d Review of the res December, 2006 out d basis. The actual Benefits" for the cr Reserves and Surp Drganic Chemicals with the Compa f Industrial Farmac	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phai my w.e.f. 01.10.20 ceutica Cantabria S	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 05 and 01.04.200 5. A., Spain, the co	nber, 2006. ed tax will be mad the above and ac cts of India Ltd., 6 respectively, a ompany has till 3	de at the end of f Iditional liability which are,pendi is per the Merg Ist December, 20
1) 2) 3) 4) 5) 6) 7)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Com held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors C approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR.	'Pharmaceuticals'. mittee, have been d Review of the res December, 2006 out d basis. The actual Benefits" for the cr Reserves and Surp Drganic Chemicals with the Compa f Industrial Farmac	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phai my w.e.f. 01.10.20 ceutica Cantabria S	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 05 and 01.04.200 5. A., Spain, the co	nber, 2006. ed tax will be mad the above and ac cts of India Ltd., 6 respectively, a ompany has till 3	de at the end of Iditional liability which are,pendi is per the Mer Ist December, 20
1) 2) 3) 4) 5) 6) 7) 8)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors C approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi	'Pharmaceuticals'. nmittee, have been d Review of the res december, 2006 out d basis. The actual Benefits" for the c Reserves and Surp Drganic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phai my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 05 and 01.04.200 5. A., Spain, the co nd, incorporated f	nber, 2006. ed tax will be mad a the above and ac cts of India Ltd., 16 respectively, a ompany has till 3 or the aforesaid p	de at the end of Iditional liability which are,pendi is per the Mer Ist December, 20 urpose.
 1) 2) 3) 4) 5) 6) 7) 8) 	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity	'Pharmaceuticals'. nmittee, have been d Review of the res december, 2006 out d basis. The actual Benefits" for the c Reserves and Surp Drganic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phai my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 05 and 01.04.200 5. A., Spain, the co nd, incorporated f	nber, 2006. ed tax will be mad a the above and ac cts of India Ltd., 16 respectively, a ompany has till 3 or the aforesaid p	de at the end of t Iditional liability which are,pendi is per the Merş Ist December, 20 urpose.
 1) 2) 3) 4) 5) 6) 7) 8) 9) 	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi. Wanbury Holding B. V. has acquired 90% of the equity Company.	'Pharmaceuticals'. mittee, have been d Review of the reg December, 2006 out d basis. The actual Benefits" for the c Reserves and Surpl Drganic Chemicals with the Compa f Industrial Farmad ary, Wanbury Holc shares of Cantabri	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phar iny w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 05 and 01.04.200 5. A., Spain, the cc nd, incorporated f	nber, 2006. ed tax will be mad a the above and ac cts of India Ltd., 16 respectively, a ompany has till 3 or the aforesaid p rter, making it sub	de at the end of f Iditional liability which are,pendi as per the Merg Ist December, 20 urpose. psidiary of the
 1) 2) 3) 4) 5) 6) 7) 8) 9) 	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b	'Pharmaceuticals'. nmittee, have been d Review of the res December, 2006 out d basis. The actual Benefits'' for the cr Reserves and Surpl Drganic Chemicals with the Compa f Industrial Farmac ary, Wanbury Hold shares of Cantabri peginning of and a	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phar iny w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 05 and 01.04.200 5. A., Spain, the cc nd, incorporated f	nber, 2006. ed tax will be mad a the above and ac cts of India Ltd., 16 respectively, a ompany has till 3 or the aforesaid p rter, making it sub	de at the end of Iditional liability which are,pendi as per the Merr lst December, 20 urpose. psidiary of the
1) 2) 3) 4) 5) 6) 7) 8) 9) 10)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b complaints from the investors and the same were resoli	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits" for the cu Reserves and Surpl Organic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc shares of Cantabri peginning of and a yed.	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phai my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa t the end of the q	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 005 and 01.04.200 5. A., Spain, the co nd, incorporated f ain during the qua- uarter. During the	nber, 2006. ed tax will be mad a the above and ac cts of India Ltd., 16 respectively, a ompany has till 3 or the aforesaid p rter, making it sub	de at the end of Iditional liability which are,pendi as per the Merr lst December, 20 urpose. psidiary of the
1) 2) 3) 4) 5) 6) 7) 8) 9) 10)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits" for the cu Reserves and Surpl Organic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc shares of Cantabri peginning of and a yed.	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phai my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa t the end of the q	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 005 and 01.04.200 5. A., Spain, the co nd, incorporated f ain during the qua- uarter. During the	nber, 2006. ed tax will be mad a the above and ac cts of India Ltd., 16 respectively, a ompany has till 3 or the aforesaid p rter, making it sub	de at the end of Iditional liability which are,pendi as per the Merr lst December, 20 urpose. psidiary of the
1) 2) 3) 4) 5) 6) 7) 8) 9) 10)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b complaints from the investors and the same were resoli	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits" for the cu Reserves and Surpl Organic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc shares of Cantabri peginning of and a yed.	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phar my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa t the end of the q f the current period	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir financial year. maceutical Produ 05 and 01.04.200 6. A., Spain, the co nd, incorporated f ain during the qua- uarter. During the l.	nber, 2006. ed tax will be made the above and access of India Ltd., 16 respectively, a company has till 3 or the aforesaid p rter, making it sub e quarter, Compan	de at the end of Iditional liability which are,pendi as per the Merr lst December, 20 urpose. psidiary of the
1) 2) 3) 4) 5) 6) 7) 8) 9) 10)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b complaints from the investors and the same were resoli	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits" for the cu Reserves and Surpl Organic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc shares of Cantabri peginning of and a yed.	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phar my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa t the end of the q f the current period	e ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferre been considered ir financial year. maceutical Produ 005 and 01.04.200 5. A., Spain, the co nd, incorporated f ain during the qua- uarter. During the	nber, 2006. ed tax will be made the above and access of India Ltd., 16 respectively, a company has till 3 or the aforesaid p rter, making it sub e quarter, Compan	de at the end of Iditional liability which are,pendi as per the Merr lst December, 20 urpose. psidiary of the
1) 2) 3) 4) 5) 6) 7) 8) 9) 10)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b complaints from the investors and the same were resoli	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits" for the cu Reserves and Surpl Organic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc shares of Cantabri peginning of and a yed.	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phar my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa t the end of the q f the current period	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir financial year. maceutical Produ 05 and 01.04.200 6. A., Spain, the co nd, incorporated f ain during the qua- uarter. During the l.	nber, 2006. ed tax will be made the above and access of India Ltd., 16 respectively, a company has till 3 or the aforesaid p rter, making it sub e quarter, Compan	de at the end of Iditional liability which are,pend as per the Mer lst December, 20 urpose. psidiary of the
1) 2) 3) 4) 5) 6) 7) 8) 9) 10)	The Company has only one segment of activity namely The above financial results reviewed by the Audit Cor- held on 31st January, 2007. The auditors of the Company have carried out a Limite The Company has utilised Rs. 4,340.18 Lacs upto 31st I Provision for income tax for the quarter is on estimate financial year. Effect of Accounting Standard 15 (Revised) "Employee any as at the beginning of the year will be given in the Above does not include financial results of Doctors O approval of appropriate authorities, to be merged Schemes(including revised) filed with BIFR. In order to acquire certain pharmaceutical business o invested Rs. 3,235.85 Lacs, in its wholly owned subsidi Wanbury Holding B. V. has acquired 90% of the equity Company. There were no investor's complaints pending at the b complaints from the investors and the same were resoli	'Pharmaceuticals'. nmittee, have been d Review of the res becember, 2006 out d basis. The actual Benefits" for the cu Reserves and Surpl Organic Chemicals with the Compa f Industrial Farmac ary, Wanbury Holc shares of Cantabri peginning of and a yed.	taken on record at sults for the quarter of the GDR issue of provision for inco urrent periods has us at the end of the Ltd. and the Phar my w.e.f. 01.10.20 ceutica Cantabria S ling B. V., Netherla a Pharma S. L., Spa t the end of the q f the current period	ended 31st Decer f Rs. 4,402.35 Lacs me tax and deferr been considered ir financial year. maceutical Produ 05 and 01.04.200 6. A., Spain, the co nd, incorporated f ain during the qua- uarter. During the l.	nber, 2006. ed tax will be made the above and access of India Ltd., 16 respectively, a company has till 3 or the aforesaid p rter, making it sub e quarter, Compan	de at the end of Iditional liability which are,pend as per the Mer Ist December, 2 urpose. psidiary of the

Document Produced by deskPDF Unregistered :: http://www.docudesk.com